MedTrace Logo

Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial

NCT00593450 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1208

Last updated 2017-08-21

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a variable schedule, and Avastin on a variable schedule.

A five year follow-up visit is being conducted in 2014 to gather information on long term outcomes.

Conditions

  • Age Related Macular Degeneration

Interventions

DRUG

ranibizumab

• 0.5 mg (0.05 mL)intravitreal injection

DRUG

bevacizumab

• 1.25 mg (0.05 mL)intravitreal injection

Sponsors & Collaborators

Principal Investigators

  • Daniel F Martin, MD · The Cleveland Clinic

  • Stuart L Fine, MD · Study Vice-Chair, University of Pennsylvania

  • Maureen G Maguire, PhD · Director of Coordinating Center, University of Pennsylvania

  • Glenn Jaffe,, MD · Director of OCT Reading Center, Duke University

  • Juan E Grunwald, MD · Principal Investigator of Photography Reading Center, Universisty of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2010-12-31
Completion
2015-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00593450 on ClinicalTrials.gov